Trial Outcomes & Findings for Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform (NCT NCT02750267)

NCT ID: NCT02750267

Last Updated: 2017-07-24

Results Overview

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

12 participants

Primary outcome timeframe

68 hours

Results posted on

2017-07-24

Participant Flow

Participant milestones

Participant milestones
Measure
Group A- Home Care Before Closed-Loop Control
In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission. Diabetes Assistant (DiAs) with Closed-Loop: All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Group B- Closed-Loop Control Before Home Care
Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission. Diabetes Assistant (DiAs) with Closed-Loop: All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Overall Study
STARTED
6
6
Overall Study
COMPLETED
6
6
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Group A- Home Care Before Closed-Loop Control
n=6 Participants
In this randomized, cross-over study, the intervention involves blood glucose control using a Closed Loop system run by the Diabetes Assistant (DiAs) during a stay at a Research House/Hotel. All subjects will have blood glucose data compared between their usual diabetes care (at home, using home insulin pump) and this Closed-Loop care (at Research House/Hotel using the DiAs system). Subjects who are randomized to Group A will have home care evaluated before the Research House/Hotel admission. Subjects in this arm will participate in CGM training and data collection prior to the Research House/Hotel admission. Diabetes Assistant (DiAs) with Closed-Loop: All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Group B- Closed-Loop Control Before Home Care
n=6 Participants
Group B is identical to Group A with the exception that usual diabetes care (at home, using home insulin pump) will be evaluated after the Research House/Hotel admission. Subjects who are randomized to Group B will participate in CGM training and data collection after the Research House/Hotel admission. As with Group A, all subjects will use Diabetes Assistant (DiAs) with Closed-Loop during the admission. Diabetes Assistant (DiAs) with Closed-Loop: All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
Total
n=12 Participants
Total of all reporting groups
Age, Continuous
7 years
n=5 Participants
7 years
n=7 Participants
7 years
n=5 Participants
Sex: Female, Male
Female
3 Participants
n=5 Participants
3 Participants
n=7 Participants
6 Participants
n=5 Participants
Sex: Female, Male
Male
3 Participants
n=5 Participants
3 Participants
n=7 Participants
6 Participants
n=5 Participants
HbA1c
7.7 percentage of HbA1C
n=5 Participants
7.6 percentage of HbA1C
n=7 Participants
7.7 percentage of HbA1C
n=5 Participants
Diabetes Duration
4.9 years
n=5 Participants
3.3 years
n=7 Participants
3.7 years
n=5 Participants

PRIMARY outcome

Timeframe: 68 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Percent of Sensor Glucose Readings Between 70-180 mg/dL
46.9 percentage of time in range
Standard Deviation 2.7
73.1 percentage of time in range
Standard Deviation 2.7

SECONDARY outcome

Timeframe: 68 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Percent of Time Sensor Glucose Readings Are <70 mg/dL
1.6 percentage of time below 70 mg/dL
Standard Deviation 1.2
1.1 percentage of time below 70 mg/dL
Standard Deviation 1.1

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 68 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Percent of Time Sensor Glucose Readings Are >180 mg/dL
51.5 percentage of time above 180 mg/dL
Standard Deviation 0.8
25.8 percentage of time above 180 mg/dL
Standard Deviation 2.8

SECONDARY outcome

Timeframe: 68 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Percent of Time Sensor Glucose Readings Are >250 mg/dL
20.8 percentage of time above 250 mg/dL
Standard Deviation 9.9
6.3 percentage of time above 250 mg/dL
Standard Deviation 5.4

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 68 hours

All subjects have CGM and handheld glucose meter output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Mean BG (as Measured by CGM)
190 mg/dL
Standard Deviation 7.4
152 mg/dL
Standard Deviation 4.2

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 72 hours

All subjects have CGM output analyzed and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 68 hours

All subjects have hypoglycemia monitored by meter analysis and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome measures
Measure
Home Care (Pump+CGM)
n=12 Participants
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 Participants
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission.
Incidence of Hypoglycemia Per Subject, Defined by Handheld Meter Glucose <70 mg/dL
4.0 events per subject, glucometer <70mg/dL
Standard Deviation 1.0
3.3 events per subject, glucometer <70mg/dL
Standard Deviation 1.0

SECONDARY outcome

Timeframe: 72 hours

All subjects have blood glucose evaluated upon rising (approximately 7 am) and compared between time on closed-loop system and time on usual care period.

Outcome measures

Outcome data not reported

Adverse Events

Home Care (Pump+CGM)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Diabetes Assistant (DiAs) With Closed-Loop Control

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Home Care (Pump+CGM)
n=12 participants at risk
All 12 subjects completed 68 hours of usual, home care using their home insulin pumps and a study CGM. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Diabetes Assistant (DiAs) With Closed-Loop Control
n=12 participants at risk
All 12 subjects used the DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a 68 hour Hotel admission. The 6 subjects in Group A completed the home care portion before the Hotel admission, and the 6 subjects in Group B completed the home care portion after the Hotel admission.
Musculoskeletal and connective tissue disorders
Sore Knee
0.00%
0/12 • Adverse event data was collect over two 72 hour periods for each subject. Over the entire study, adverse events were collected over a 216 hour period (Group A's 72 hr home period, 72 hr hotel period, Group B's 72 hr home period).
8.3%
1/12 • Number of events 1 • Adverse event data was collect over two 72 hour periods for each subject. Over the entire study, adverse events were collected over a 216 hour period (Group A's 72 hr home period, 72 hr hotel period, Group B's 72 hr home period).

Additional Information

Dr. Daniel R. Chernavvsky

Center for Diabetes Technology

Phone: 4342431395

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place